SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (568)2/17/1999 11:01:00 PM
From: jeffbas  Read Replies (1) of 1073
 
Richard the following was allegedly said (per Yahoo 7097) on the ENMD conference call:

On the molecule recently licensed by Children's to GZMO: ENMD “knows the molecule well” and
passed on it because, as Eye8 and others have already posted here, ENMD believes that it already has
intellectual property rights to the entire CLASS of compounds of which the GZMO molecule is a
member, according to ENMD's counsel. The relevant filings at PTO were made last year and the
patents are still being prosecuted.

Frankly I am flabberghasted, and it explains GZMO's drop today. Is it conceivable that Children's would have licensed a product to which they no longer had the rights or GZMO would have entered into such an agreement if what ENMD claims is true? Obviously I have to call the company but wanted some informed opinion in advance as to whether my uninformed surprise is warranted.

Thanks for your help.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News